首页> 中文期刊> 《亚洲男性学杂志:英文版》 >Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation

Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation

         

摘要

Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the ifrst drug approved for the on?demand treatment of premature ejaculation(PE). Our objective in this study was to characterize the efifcacy of on?demand dapoxetine(30 and 60mg) and daily paroxetine(20mg) usage in treating PE. We conducted a 1 month study involving a total of 150patients. Patients were divided into three groups of 50. Group1 were treated with on?demand dapoxetine(30mg), Group2 with on?demand dapoxetine(60mg) and Group3 with daily paroxetine(20mg). Our outcome measurement was increased from baseline intravaginal ejaculatory latency time(IELT) after treatment. The IELT increased from baseline to posttreatment by 117%, 117% and 170% in the paroxetine group(P0.05), while the 60mg dapoxetine group had a larger posttreatment IELT increase compared with the 30mg dapoxetine(P<0.05) and paroxetine(P<0.01) groups. Dapoxetine(60mg) 1–3h before planned intercourse is a very effective treatment modality for PE. However, an on?demand dose of 30mg dapoxetine is no more effective than the currently prescribed paroxetine treatment.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号